Intravenous fosfomycin for the treatment of hospitalized patients with serious infections

References

• Jim O'Neil. Review on antimicrobial resistance: tackling drug-resistant infections globally: final report and recommendations. 2016. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
   Google Scholar
• Dasgupta S, Das S, Chawan NS, et al. Nosocomial infections in the intensive care unit: incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med. 2015;19(1):14–20.
   PubMed Web of Science ®Google Scholar
• Parker SL, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents. 2013;59(10):6471–6476.
   Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347.
   PubMed Web of Science ®Google Scholar
• Castaneda-Garcia A, Blazquez J, Rodriguez-Rojas A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics (Basel, Switzerland). 2013;2(2):217–236.
   PubMedGoogle Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. http://www.eucast.org.
   Google Scholar
• Datapharm Communications Limited, Electronic Medicines Compendium (eMC). Fomicyt 40 mg/ml powder for solution for infusion. 2014. https://www.medicines.org.uk/emc/medicine/28971
   Google Scholar
• Zavante Therapeutics. Safety and efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections (ZEUS). Bethesda (MD): National Library of Medicine (US); 2016. NLM Identifier: 02753946. Available form: www.ClinicalTrials.gov
   Google Scholar
• Docobo-Perez F, Drusano GL, Johnson A, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602–5610.
   PubMed Web of Science ®Google Scholar
• Bhavnani S, Trang M, Rubino C, et al. Pharmacokinetics-Pharmacodynamics (PK-PD) target attainment analyses to support ZTI-01 (fosfomycin for injection) dose selection for patients with complicated urinary tract infections. In: ASM microbe. New Orleans (LA); 2017.
   Google Scholar
• Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22:273–280.
   PubMed Web of Science ®Google Scholar
• Parker SL, Frantzeskaki F, Wallis SC, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59:6471–6476.
   PubMed Web of Science ®Google Scholar
• Yu X-H, Song X-J, Cai Y, et al. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot. 2010;63(11):657–659.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Legakis NJ, Triarides N, et al. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–285.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Shen P, Wei Z, et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents. 2015;45(1):66–70.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54(1):526–529.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Griffin MA, Deshpande LM, et al. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY antimicrobial surveillance program in 2014 and 2015. Antimicrob Agents Chemother. 2016;60(9):5623–5624.
   PubMed Web of Science ®Google Scholar
• Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44:182–189.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–59.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Mundy LM. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis. 2010;51(11):1352–1354.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents. 2012;39:271–272.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat RTV. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–5601.
   PubMed Web of Science ®Google Scholar
• Perez F, El Chakhtoura NG, Papp-Wallace KM, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761–781.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin. 2015;33(5):337.e331–337.e321.
   Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Kirby W. Pharmacokinetics of fosfomycin. Chemotherapy. 1977;23:141–151.
   PubMed Web of Science ®Google Scholar
• Farago E, Kiss I, Nabradi Z. Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol. 1980;18:554–558.
   PubMed Web of Science ®Google Scholar
• Berthelot G, Bergogne-Berezin E, Kafe H, et al. Penetration of fosfomycin into bronchial secretions. Pathol Biol (Paris). 1983;31:519–521.
   PubMed Web of Science ®Google Scholar
• Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother. 2010;65:995–998.
   PubMed Web of Science ®Google Scholar
• Pfeifer G, Frenkel C, Entzian W. Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res. 1985;5(3):171–174.
   PubMedGoogle Scholar
• Simkins J, Fan J, Camargo JF, et al. Intravenous fosfomycin treatment for carbapenem-resistant Klebsiella pneumoniae in the United States. Ann Pharmacother. 2015;49(10):1177–1178.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;2010(16):2.
   Google Scholar
• Florent A, Chichmanian RM, Cua E, et al. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37:82–83.
   PubMed Web of Science ®Google Scholar
• Kusachi S, Nagao J, Saida Y, et al. Antibiotic time-lag combination therapy with fosfomycin for postoperative intra-abdominal abscesses. J Infect Chemother. 2011;17(1):91–96.
   PubMed Web of Science ®Google Scholar
• Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-E79.
   Web of Science ®Google Scholar
• del Río A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clinical Infect Dis. 2014;59:1105–1112.
   PubMed Web of Science ®Google Scholar
• Chen J, Luo Y, Zhang S, et al. Community-acquired necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a Chinese teenager: case report and literature review. Int J Infect Dis. 2014;26:17–21.
   PubMed Web of Science ®Google Scholar
• Chen L-Y, Huang C-H, Kuo S-C, et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011;11:152.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother. 2012;67(11):2777–2779.
   PubMed Web of Science ®Google Scholar
• Vergara-Lopez S, Dominguez M, Conejo M, et al. Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-beta-lactamase-producing Klebsiella oxytoca. J Antimicrob Chemother. 2015;70(1):313–315.
   PubMed Web of Science ®Google Scholar
• Miro JM, Entenza JM, Del Rio A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012;56(8):4511–4515.
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.
   PubMed Web of Science ®Google Scholar
• Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793–1800.
   PubMed Web of Science ®Google Scholar
• Shaw E, Miró JM, Puig-Asensio M, et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open. 2015;5:e006723.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Wang R, Xu-Hong Y, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255–268.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Marshall J, Anzueto A, et al. and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Fridken SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(9):235–241.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–142.
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 2010;14:e764–e769.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology international conference on emerging infectious diseases, 2002. Emerg Infect Dis. 2002;8:8–9.
   Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Spanish Network for Research in Infectious Diseases. Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E. coli (FOREST). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016
   Google Scholar
• Kawabata T, Yokota M, Mayama T, et al. A post-marketing surveillance study of fosfomycin sodium for injectionA nationwide prospective study of safety in 100, 000 cases. Jpn J Chemother. 2000;48(11):851–874.
   Google Scholar
• Coukell A, Shore C. A scientific roadmap for antibiotic discovery. 2016. http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf
   Google Scholar
• Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect. 2008;14(Suppl 3):15–21.
   PubMed Web of Science ®Google Scholar